Show simple item record

dc.contributor.authorButters, D
dc.contributor.authorWhitehouse, M
dc.date.accessioned2017-05-03T14:18:59Z
dc.date.available2017-05-03T14:18:59Z
dc.date.issued2009
dc.date.modified2011-03-31T04:47:47Z
dc.identifier.issn1756-1841
dc.identifier.doi10.1111/j.1756-185X.2009.01427.x
dc.identifier.urihttp://hdl.handle.net/10072/37900
dc.description.abstractThis article is a plea to find (better) ways to extend the benefits of anti-cytokine therapies to ensure they will become available as widely as possible. Pessimistically, this will probably involve substituting more affordable, although somewhat less specific, non-biological agents for present target-specific bio-DMARDs (disease-modifying antirheumatic drugs) to ensure far wider distribution of benefits. Optimistically, new developments in technology and bio-engineering might dramatically reduce costs of present 'biological' therapies. (The antibiotics we now take for granted were once also horrendously expensive.). Pragmatically, one goal for this mission should include seriously pursuing more research and pilot clinical trials of non-protein combination therapies able to control: (i) TNF or other pro-inflammatory cytokines; and also (ii) other mediators sustaining chronic inflammation (?pain, effusion, fibrosis, porosis, etc.). This can be immediately facilitated by drawing upon the immense resources of non-prescription Asia-Pacific traditional therapies - particularly when these have already been shown to either reduce TNF synthesis or control TNF-induced responses in preclinical studies. Could this be a major goal for the next decade, helping rectify some of the omissions of the current Bone & Joint Decade 2000-2010?
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageeng
dc.language.isoen_AU
dc.publisherWiley-Blackwell Publishing Asia
dc.publisher.placeAustralia
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom299
dc.relation.ispartofpageto306
dc.relation.ispartofissue4
dc.relation.ispartofjournalInternational Journal of Rheumatic Diseases
dc.relation.ispartofvolume12
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchMedical Microbiology
dc.subject.fieldofresearchcode119999
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1107
dc.subject.fieldofresearchcode1108
dc.titleBeyond conventional DMARDs: extending TNF-regulant therapies to the vast majority/less privileged who do need them
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2009
gro.hasfulltextNo Full Text
gro.griffith.authorWhitehouse, Michael


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record